Molecular subtypes of pancreatic cancer based on miRNA expression profiles have independent prognostic value

Journal of Gastroenterology and Hepatology (Australia)

Volumn 31, Issue 6, 2016, Pages 1160-1167

  Namkung, Junghyun ^a   Kwon, Wooil ^b,c   Choi, Yonwhan ^a   Yi, Sung Gon ^a   Han, Sangjo ^a   Kang, Mee Joo ^b   Kim, Sun Whe ^b   Park, Taesung ^d   Jang, Jin Young ^b  

^a SK Telecom   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Sungkyunkwan University School of Medicine   (South Korea)

^d Seoul National University   (South Korea)

Author keywords

MiRNA profile; Molecular subtype; Pancreatic ductal adenocarcinoma; Prognosis

Indexed keywords

CYCLOOXYGENASE 2; FLUOROURACIL; GEMCITABINE; MICRORNA; MICRORNA 145; PROTEIN P53; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; DISEASE FREE SURVIVAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREAS RESECTION; PANCREATICODUODENECTOMY; PRIORITY JOURNAL; SURVIVAL TIME; CELL DIFFERENTIATION; CHI SQUARE DISTRIBUTION; CLASSIFICATION; CLUSTER ANALYSIS; DNA MICROARRAY; GENE EXPRESSION PROFILING; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY; PREDICTIVE VALUE; PROCEDURES; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; SOUTH KOREA; TUMOR INVASION;

AGED; BIOMARKERS, TUMOR; CARCINOMA, PANCREATIC DUCTAL; CELL DIFFERENTIATION; CHI-SQUARE DISTRIBUTION; CLUSTER ANALYSIS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM INVASIVENESS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PANCREATIC NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REGRESSION ANALYSIS; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES;

EID: 84971238315     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.13253     Document Type: Article

References (39)

1. Sethi S, Kong D, Land S, Dyson G, Sakr WA, Sarkar FH. Comprehensive molecular oncogenomic profiling and miRNA analysis of prostate cancer. Am. J. Transl. Res. 2013; 5: 200-11.
2. Siomi H, Siomi MC. Posttranscriptional regulation of microRNA biogenesis in animals. Mol. Cell 2010; 38: 323-32.
3. Carthew RW, Sontheimer EJ. Origins and mechanisms of miRNAs and siRNAs. Cell 2009; 136: 642-55.
4. Gu S, Kay MA. How do miRNAs mediate translational repression? Silence 2010; 1: 11.
5. Kim GH. MicroRNA regulation of cardiac conduction and arrhythmias. Transl. Res. 2013; 161: 381-92.
6. Locke JM, Harries LW. MicroRNA expression profiling of human islets from individuals with and without type 2 diabetes: promises and pitfalls. Biochem. Soc. Trans. 2012; 40: 800-3.
7. Wang W, Kwon EJ, Tsai LH. MicroRNAs in learning, memory, and neurological diseases. Learn. Mem. 2012; 19: 359-68.
8. Gupta A, Swaminathan G, Martin-Garcia J, Navas-Martin S. MicroRNAs, hepatitis C virus, and HCV/HIV-1 co-infection: new insights in pathogenesis and therapy. Viruses 2012; 4: 2485-513.
9. Farazi TA, Hoell JI, Morozov P, Tuschl T. MicroRNAs in human cancer. Adv. Exp. Med. Biol. 2013; 774: 1-20.
10. Iorio MV, Croce CM. Causes and consequences of microRNA dysregulation. Cancer J. 2012; 18: 215-22.
11. Esquela-Kerscher A, Slack FJ. Oncomirs-microRNAs with a role in cancer. Nat. Rev. Cancer 2006; 6: 259-69.
12. Xia H, Hui KM. MicroRNAs involved in regulating epithelial-mesenchymal transition and cancer stem cells as molecular targets for cancer therapeutics. Cancer Gene Ther. 2012; 19: 723-30.
13. Srivastava SK, Arora S, Singh S, Bhardwaj A, Averett C, Singh AP. MicroRNAs in pancreatic malignancy: progress and promises. Cancer Lett. 2014; 347: 167-74.
14. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J. Clin. 2013; 63: 11-30.
15. Papaconstantinou IG, Manta A, Gazouli M et al. Expression of microRNAs in patients with pancreatic cancer and its prognostic significance. Pancreas 2013; 42: 67-71.
16. MacQeen J. Some methods for classification and analysis of multivariate observations. Proc. Fifth Berkeley Symp. Math Stat. Probab 1967; 1: 281-97.
17. Tibshirani R, Walther G, Hastie T. Estimating the number of clusters in a data set via the gap statistic. Journal of the Royal Statistical Society: Series B (Statistical Methodology) 2001; 63: 411-23.
18. Zou H, Hastie T. Regression Shrinkage and Selection via the Elastic Net, With Applications to Microarrays. Technical Report, Department of Statistics, Stanford University, 2003
19. Zou H, Hastie T. Regularization and variable selection via the elastic net. J. R. Stat Soc Ser B Stat. Methodol 2005; 67: 301-20.
20. Jiang B, Gu Y, Chen Y. Identification of novel predictive markers for the prognosis of pancreatic ductal adenocarcinoma. Cancer Invest. 2014; 32: 218-25.
21. Brennan MF, Kattan MW, Klimstra D, Conlon K. Prognostic nomogram for patients undergoing resection for adenocarcinoma of the pancreas. Ann. Surg. 2004; 240: 293-8.
22. Winter JM, Cameron JL, Campbell KA et al. 1423 pancreaticoduodenectomies for pancreatic cancer: a single-institution experience. J.Gastrointest. Surg. 2006; 10: 1199-210 discussion 1210-1211.
23. Fong ZV, Winter JM. Biomarkers in pancreatic cancer: diagnostic, prognostic, and predictive. Cancer J. 2012; 18: 530-8.
24. Schultz NA, Dehlendorff C, Jensen BV et al. MicroRNA biomarkers in whole blood for detection of pancreatic cancer. JAMA 2014; 311: 392-404.
25. Brand RE, Adai AT, Centeno BA et al. A microRNA-based test improves endoscopic ultrasound-guided cytologic diagnosis of pancreatic cancer. Clin. Gastroenterol. Hepatol. 2014; 12: 1717-23.
26. Ohuchida K, Mizumoto K, Kayashima T et al. MicroRNA expression as a predictive marker for gemcitabine response after surgical resection of pancreatic cancer. Ann. Surg. Oncol. 2011; 18: 2381-7.
27. Iwagami Y, Eguchi H, Nagano H et al. miR-320c regulates gemcitabine-resistance in pancreatic cancer via SMARCC1. Br. J. Cancer 2013; 109: 502-11.
28. Yu J, Ohuchida K, Mizumoto K et al. MicroRNA, hsa-miR-200c, is an independent prognostic factor in pancreatic cancer and its upregulation inhibits pancreatic cancer invasion but increases cell proliferation. Mol. Cancer 2010; 9: 169.
29. Greither T, Grochola LF, Udelnow A, Lautenschlager C, Wurl P, Taubert H. Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated with poorer survival. Int. J. Cancer 2010; 126: 73-80.
30. Dillhoff M, Liu J, Frankel W, Croce C, Bloomston M. MicroRNA-21 is overexpressed in pancreatic cancer and a potential predictor of survival. J. Gastrointest. Surg. 2008; 12: 2171-6.
31. Bloomston M, Frankel WL, Petrocca F et al. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA 2007; 297: 1901-8.
32. Petrelli F, Coinu A, Borgonovo K, Cabiddu M, Barni S. Progression-free survival as surrogate endpoint in advanced pancreatic cancer: meta-analysis of 30 randomized first-line trials. Hepatobiliary Pancreat. Dis. Int. 2016; 14: 124-31.
33. Milella M, Bria E, Carlini P et al. Surrogate endpoints for overall survival (OS) in advanced pancreatic cancer (APC): analysis of randomized clinical trials (RCTs) exploring gemcitabine (G)-based combinations. J. Clin. Oncol. ASCO Annual Meeting Proceedings 2007; 25 (18S (June 20 Supplement)): 4575.
34. Broderick J a, Zamore PD. MicroRNA therapeutics. Gene Ther. 2011; 18: 1104-10.
35. Kota J, Chivukula RR, O'Donnell K a et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 2009; 137: 1005-17.
36. Jacobsen A, Silber J, Harinath G, Huse JT, Schultz N, Sander C. Analysis of microRNA-target interactions across diverse cancer types. Nat. Struct. Mol. Biol. 2013; 20: 1325-32.
37. Speranza MC, Frattini V, Pisati F et al. NEDD9, a novel target of miR-145, increases the invasiveness of glioblastoma. Oncotarget. 2012; 3: 723-34.
38. Li L, Hu X, Yang Z et al. Establishing reliable miRNA-cancer association network based on text-mining method. Comput. Math. Methods Med. 2014; 2014: 746979.
39. Ma MZ, Kong X, Weng MZ. Candidate microRNA biomarkers of pancreatic ductal adenocarcinoma: meta-analysis, experimental validation and clinical significance. J. Exp. Clin. Cancer Res. 2013; 32: 71.